Karyopharm Stock Up Even As FDA Delays Selinexor NDA Verdict
Zacks Investment Research | Mar 17, 2019 11:26PM ET
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were up almost 7.1% after the company announced that the FDA has extended its action date for the new drug application (NDA) of oral selective inhibitor of nuclear export (SINE) compound, selinexor, by three months. The company is looking to get an accelerated approval for the candidate to treat patients with relapsed-refractory multiple myeloma (MM), who have received at least three prior lines of therapy.
Previously, the regulatory body was expected to render its decision on Apr 6, 2019. However, the FDA delayed its verdict by three months and has now set an action date of Jul 6 this year.
However, shares of Karyopharm have plunged 49.7% so far this year against the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.